Exosens Shares: Stock Nears Resistance Following Annual Results Exceeding Expectations
Exosens stock is up 1.71% this Wednesday morning, trading at 59.60 euros, following the publication of annual results for 2025 that surpassed the company's targets. Additionally, two analyst offices revised their recommendations today, sending mixed signals about the stock's valuation.
Annual Financial Performance
Exosens revealed its annual accounts for 2025 on Monday, reporting a consolidated revenue of 468.2 million euros, marking a 22.1% increase year-over-year. The specialist in detection and imaging technologies exceeded its own forecasts, driven by particularly strong business activity in the defense and surveillance segments. Night vision, a historical area of expertise for the group, was one of the main drivers of this momentum. On the markets, the stock has shown remarkable performance with a gain of over 45% over three months and a doubling of its value over a year. The price is now close to the resistance threshold identified at 60.50 euros, a key technical level. If surpassed, the upper Bollinger band at 61.39 euros could be the next marker to watch. The RSI, at 57, indicates a moderately bullish momentum, without any excessive tension at this stage.
Updated Analyst Evaluations
Two financial institutions updated their evaluation of the stock on February 25. Deutsche Bank raised its price target from 52 to 55 euros, while maintaining a 'hold' recommendation. This new target remains 7.7% below the current price, indicating caution about the potential for short-term revaluation. On the other hand, BNP Paribas Exane significantly raised its target from 49 to 64 euros, with an 'outperform' rating. This position implies an appreciation potential of about 7.4% compared to the current level. The discrepancy between these two views reflects different assumptions about the group's ability to continue its growth trajectory beyond 2025. The next financial milestones are set for April 27, with the publication of the results for the first quarter of 2026, followed by the annual general meeting scheduled for May 22.
